Sangamo Therapeutics, Inc.
Engineered target specific nucleases
Last updated:
Abstract:
Described herein are engineered nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity is increased.
Status:
Grant
Type:
Utility
Filling date:
8 Feb 2019
Issue date:
2 Aug 2022